AI for Antibody Drug Discovery

Exscientia applied its AI-driven drug discovery platform to antibody therapeutics development. The company's platform integrated machine learning with automated laboratory systems to accelerate antibody lead identification and optimization. Exscientia's AI approach enabled rapid iteration between computational predictions and experimental validation, reducing the timeline for antibody therapeutic development. The company applied its platform across multiple therapeutic areas including oncology, immunology, and infectious diseases. Exscientia's AI platform has generated multiple clinical-stage assets through these approaches. Note: Exscientia merged with Recursion in 2024 to create a leading AI-first biopharmaceutical company combining Exscientia's automated synthesis capabilities with Recursion's morphological profiling platform.